Skip to main content Skip to main menu
UF Health University of Florida
Division of Hematology & Oncology Department of Medicine in the College of Medicine
Erin Dean

Erin Dean, MD

Assistant Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832
Business Email: erin.dean@ufl.edu

About Erin Dean

Erin Dean, MD is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of Florida College of Medicine.

Dr. Dean received her undergraduate degree in Biomedical Engineering, Premedical, magna cum laude, from the University of California, Irvine and her medical degree from the University of South Florida Morsani College of Medicine in Tampa, Florida.

She finished her residency in Internal Medicine at the University of South Florida Morsani College of Medicine, where she received the Chairman’s Humanism Award for consistently demonstrating compassion, respect, and empathy in the delivery of patient-centered care and service to others. Dr. Dean completed a fellowship in Hematology-Oncology, followed by a dedicated year of training in Blood & Marrow Transplant and Cellular Immunotherapy, at Moffitt Cancer Center.

Her research focuses on the advancement of cellular immunotherapy and the development of new biomedical technology aimed to help patients with malignant hematologic disorders. She is involved in leading clinical trials and conducting translational research within the field. Dr. Dean aims to provide outstanding clinical care for patients with lymphoma and multiple myeloma undergoing CAR T-cell therapy and hematopoietic stem cell transplantation.

Dr. Dean is board certified in Internal Medicine, Medical Oncology, and Hematology. She is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO).

Accomplishments

Chairman's Humanism Award
2016 · University of South Florida Health
Outstanding Performance in Doctoring
2011-2012 · University of South Florida

Teaching Profile

Courses Taught
2022
PAS5010 Intro to Medicine 1
2024
BMS6631 Hematology

Board Certifications

  • Hematology
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Cancer
  • Hematology and Oncology
Areas of Interest
  • Lymphoma
  • Multiple myeloma

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-3153-223X

Areas of Interest
  • CAR T-cell therapy
  • Cellular Immunotherapy
  • Hematopoietic Stem Cell Transplantation
  • Lymphoma
  • Malignant Hematologic Disorders
  • Multiple Myeloma

Publications

2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.
Blood cancer discovery. 5(2):106-113 [DOI] 10.1158/2643-3230.BCD-23-0056. [PMID] 38194367.
PubMed · Publisher’s Site
2024
Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report.
Case reports in oncology. 17(1):75-81 [DOI] 10.1159/000535426. [PMID] 38196817.
PubMed · Publisher’s Site
2023
Central nervous system manifestations as initial presentation of plasma cell disorders: Differential management of 3 cases based on disease extent
Current Problems in Cancer: Case Reports. 11 [DOI] 10.1016/j.cpccr.2023.100247.
Publisher’s Site
2023
Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma.
Blood advances. 7(16):4608-4618 [DOI] 10.1182/bloodadvances.2022009426. [PMID] 37126659.
PubMed · Publisher’s Site
2023
Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease.
Radiology case reports. 18(3):1093-1098 [DOI] 10.1016/j.radcr.2022.12.053. [PMID] 36660565.
PubMed · Publisher’s Site
2023
Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers.
Frontiers in immunology. 14 [DOI] 10.3389/fimmu.2023.994520. [PMID] 36875072.
1 citation · PubMed · Publisher’s Site
2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Science advances. 9(38) [DOI] 10.1126/sciadv.adg3919. [PMID] 37738350.
1 citation · PubMed · Publisher’s Site
2022
Viral Clearance with Neutrophil Recovery in a Patient with Active COVID-19 Infection and Refractory Acute Myeloid Leukemia Who Underwent Successful Reinduction with Cytarabine/Idarubicin.
Case reports in oncology. 15(2):705-712 [DOI] 10.1159/000525766. [PMID] 36157697.
1 citation · PubMed · Publisher’s Site
2021
Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.
Transplantation and cellular therapy. 27(7):620.e1-620.e9 [DOI] 10.1016/j.jtct.2021.03.026. [PMID] 33798768.
14 citations · PubMed · Publisher’s Site
2021
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(27):3034-3043 [DOI] 10.1200/JCO.21.00377. [PMID] 34133196.
70 citations · PubMed · Publisher’s Site
2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.
Blood. 137(19):2621-2633 [DOI] 10.1182/blood.2020007445. [PMID] 33512407.
119 citations · PubMed · Publisher’s Site
2020
Diffuse Intrasinusoidal Hepatic Metastasis from Breast Cancer Presenting as Liver Failure: Effective and Rapid Treatment with Weekly Low-Dose Adriamycin.
The American journal of case reports. 21 [DOI] 10.12659/AJCR.924141. [PMID] 32877389.
1 citation · PubMed · Publisher’s Site
2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.
Blood advances. 4(14):3268-3276 [DOI] 10.1182/bloodadvances.2020001900. [PMID] 32702097.
124 citations · PubMed · Publisher’s Site
2017
Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention
Bone Marrow Transplantation. 52(7):1003-1009 [DOI] 10.1038/bmt.2017.63. [PMID] 28368376.
15 citations · PubMed · Publisher’s Site

Grants

Sep 2023 ACTIVE
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion with Fludarabine, Cyclophosphamide, and ALLO-647, vs Fludarabine and Cyclophosphamide Alone, in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy.
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO via ALLOGENE THERAPEUTICS
Sep 2022 ACTIVE
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin
Role: Principal Investigator
Funding: ARTIVA BIOTHERAPEUTICS
Jul 2022 ACTIVE
Evaluating soluble B-cell maturation antigen as a new serum marker of minimal residual disease in patients with Multiple Myeloma
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH

Education

Fellowship in Blood & Marrow Transplant and Cellular Immunotherapy
2020-2021 · Moffitt Cancer Center
Fellowship in Hematology-Oncology
2017-2020 · University of South Florida
Residency in Internal Medicine
2014-2017 · University of South Florida
Medical Degree
2010-2014 · University of South Florida
Bachelor of Science in Biomedical Engineering
2004-2008 · University of California – Irvine

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Business:
erin.dean@ufl.edu
Addresses:
Business Mailing:
PO Box 100278
 GAINESVILLE FL 32610
Business Street:
PO Box 100278
 GAINESVILLE FL 32610